JAMA Author Interviews

The National Academy of Medicine's 2000 report "To Err Is Human" launched the health care quality movement in the US. Victor Dzau, MD, president of the National Academy of Medicine, and Don Berwick, MD, MPP, from the Institute for Healthcare Improvement, discuss progress to date in advancing quality and prospects for improving outcomes and reducing harms, errors, and cost in the next 20 years. Recorded December 22, 2020. Related Article(s): Two Decades Since To Err Is Human

Interview with Geoffrey S. Ginsburg, MD, PhD, author of Digital Health—The Need to Assess Benefits, Risks, and Value

With coronavirus vaccines now available, what are the timeline and prospects for "herd immunity" and return to a new normal? Marc Lipsitch, DPhil, of Harvard T.H. Chan School of Public Health returns to JAMA's Q&A series with Paul D. Biddinger, MD, director of Massachusetts General Hospital's Center for Disaster Medicine, to discuss. Recorded December 17, 2020. Related Article(s): COVID-19 Vaccines and Herd Immunity The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines Herd Immunity and Implications for SARS-CoV-2 Control Herd Immunity as a Coronavirus Pandemic Strategy

Peter W. Marks, MD, PhD, and Stephen M. Hahn, MD, return to JAMA's Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the data, the weekend's EUA designation (Pfizer/BioNTech), and the process for future full licensure and postmarketing safety surveillance. Dr Marks directs the US FDA's Center for Biologics Evaluation and Research (CBER). Dr Hahn is commissioner of the US Food and Drug Administration. Recorded December 14, 2020. Related Article(s): Behaviorally Informed Strategies for a National COVID-19 Vaccine Promotion Program

Anthony S. Fauci, MD, returns to JAMA's Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the public data, deliberations at Thursday's FDA Advisory Committee meeting, and prospects for an agency Emergency Use Authorization designation, licensure, and rollout. Recorded December 11, 2020. Related Article(s): Coronavirus Infections—More Than Just the Common Cold

Interview with David W. Baker, MD, MPH, author of Trust in Health Care in the Time of COVID-19

Interview with Chyke A. Doubeni, MD, MPH, USPSTF member and coauthor of USPSTF Recommendation: Screening for Hepatitis B Virus Infection in Adolescents and Adults

The COVID Tracking Project, launched by The Atlantic, collects and publishes data required to understand the COVID-19 outbreak in the US, including data on race and ethnicity needed to understand health inequities in the outbreak. Atlantic Monthly journalists Alexis C. Madrigal and Erin Kissane join JAMA's Q&A series to describe the project and their experience developing a database for fact-based health reporting on the pandemic. Recorded December 10, 2020.

The National Asthma Education and Prevention Program (NAEPP) of the NIH has updated its guideline recommendations for diagnosis and treatment of asthma patients. Michelle M. Cloutier, MD, from UConn Health, Stephanie Lovinsky-Desir, MD, of Columbia University Irving Medical Center, and JAMA Associate Editor George O'Connor, MD, MS, from Boston Medical Center join JAMA's Q&A series to discuss what's new, including revised advice about • Use of intermittent inhaled corticosteroids (ICSs) • Use of add-on long-acting muscarinic antagonists (LAMAs) • Use of fractional exhaled nitric oxide (FeNO) measurement as a diagnostic biomarker • Monitoring response to therapy • Indoor allergen mitigation strategies • Safety and efficacy of subcutaneous and sublingual immunotherapy • Use of bronchial thermoplasty Recorded December 8, 2020 Related Article(s): Managing Asthma in Adolescents and Adults

With the Pfizer and Moderna coronavirus vaccines reportedly under review at the US FDA for Emergency Use Authorization (EUA), Paul A. Offit, MD, of the Children's Hospital of Philadelphia, returns to JAMA's Q&A series to provide an update on what to expect, prospects for vaccine rollout and distribution in the coming months, and ongoing safety surveillance. Recorded December 2, 2020. Related Article: Developing a SARS-CoV-2 Vaccine at Warp Speed